Campbell 2005.

Study characteristics
Methods	Study design: RCT Number randomized: 22; 12 to the exercise group and 10 to the control group Study start and stop dates: not reported Length of intervention: 12 weeks Length of follow‐up: to end of the intervention
Participants	Type cancer: breast cancer Time since cancer diagnosis: not reported Time in active treatment: not reported Inclusion criteria: had surgery undergoing adjuvant therapy Eligibility criteria related to interest or ability, or both, to exercise: already exercising vigorously 3 times per week for 20 minutes or more Exclusion criteria: uncontrolled cardiac or hypertensive disease respiratory disease cognitive dysfunction Gender: female Current age, mean (SD) years: exercise group: 48 (10) years control group: 47 (5) years Age at cancer diagnosis: not reported Ethnicity/race: not reported Education level: not reported SES, Carstairs Deprivation Index: exercise group: 3.0 control group: 3.8 Employment status: not reported Comorbidities: not reported Past exercise history, mean minutes of physical activity per week (SD): exercise group: 330 (71) minutes control group: 421 (191) minutes On hormone therapy: not reported
Interventions	12 participants assigned to the exercise intervention, including: supervised exercise program consisting of: warm‐up 10 to 20 minutes' exercise including walking, cycling, low‐level aerobics, muscle‐strengthening exercises, circuits, etc. cool down relaxation period discussion targeting different motivational factors, 6 different themes discussed twice during the 12‐week intervention Type exercise (aerobic/anaerobic): aerobic Intensity of the experimental exercise intervention: moderate, 60% to 75% age‐adjusted HR maximum Frequency: twice per week Duration of individual sessions: not reported Duration of exercise program: 12 weeks Total number of exercise sessions: 24 sessions Format: group Facility: facility Professionally led: unclear Adherence: 10 of 12 women completed that 12‐week intervention. Participants completed an average of 70% of the total number of sessions 10 participants assigned to control group, including: usual care Contamination of control group: not reported
Outcomes	Primary outcome: change in HRQoL between baseline and 12 weeks, as assessed by FACT‐G Other HRQoL outcomes included: fatigue, assessed using the PFS HRQoL, assessed using FACT‐B functional well‐being, assessed using the FACT‐B subscale PWB, assessed using the FACT‐B subscale breast cancer concerns, assessed using the FACT‐B subscale satisfaction, assessed using the SWLS Other outcomes included: 12‐MWT perceived expectation of treatment, assessed using the Perceived Expectations and Benefits of Total Care Outcomes were measured at baseline and 12 weeks: exercise group: n = 12 at baseline, n = 10 at 12 weeks control group: n = 10 at baseline, n = 9 at 12 weeks Subgroup analysis: none reported Adverse events: none reported
Notes	Country: UK/Scotland Funding: Greater Glasgow NHS Trust
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The generation of the random sequence was not described
Allocation concealment (selection bias)	Unclear risk	Whether the treatment assignment was concealed from study personnel and participants was not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Owing to the nature of the intervention, it was not possible to conceal allocation to the intervention from the participants
Blinding of outcome assessment (detection bias) All outcomes	High risk	Allocation to the intervention was not concealed from the study personnel
Incomplete outcome data (attrition bias) All outcomes	High risk	Analyses were not conducted on an ITT basis and the treatment of missing data was not described
Selective reporting (reporting bias)	Low risk	There appears to be no selective reporting of outcomes
Other bias	Low risk	The trial appears to be free of other problems that could put it at a high risk of bias